Nkarta Inc (NKTX)

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs...

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage...

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP) A clinical-stage immuno-oncology company has moved three...

The $13 Million Company Teaching the Immune System to Hunt Cancer

The $13 Million Company Teaching the Immune System to Hunt Cancer Canada NewsWire NEW YORK, May 29, 2026...

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19...

Form 8-K - Current report

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in...